Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines through an extensive global network that spans more than 120 different countries. Celltrion Healthcare provides REMSIMA, the world's first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of autoimmune disease, and innovative biopharmaceutical medications to help increase patient access to advanced therapies around the world.
For additional information on our guidelines, please visit
https://bit.ly/3BnYi2c
Location: South Korea, Incheon
Employees: 51-200
Phone: +82 32-850-6400
Founded date: 1999
Investors 2
| Date | Name | Website |
| - | One Equity... | oneequity.... |
| - | Temasek Ho... | temasek.co... |
Mentions in press and media 5
| Date | Title | Description | Source |
| 15.02.2024 | Greg Belinfanti Appointed President Of One Equity Partner; D... | One Equity Partners (“OEP”), a middle-market private equity firm, today announced that Greg Belinf... | oneequity.... |
| 15.11.2021 | Celltrion Receives CHMP Positive Opinion for regdanvimab (CT... | INCHEON, Korea - Celltrion Group announced that the European Medicine's Agency's (EMA) Committee for... | marketscre... |
| 01.04.2021 | CELLTRION, INC. Celltrion : Healthcare receives positive CH... | INCHEON, South Korea - Celltrion Healthcare today announced that the Committee for Medicinal Product... | marketscre... |
| 26.03.2021 | EMA: Ongoing study data of Celltrion’s mAb enough to al... | The European Medicines Agency added another monoclonal antibody to the continent’s Covi... | endpts.com... |
| 07.06.2017 | Term Sheet — Wednesday, June 7 | 500 Hello, it’s Fortune 500 day! The 2017 list is live here. For 63 years, this list has ranked the ... | fortune.co... |